For full access to this article login to GEN Select now.
There are a growing number of companies with only one drug candidate in development and none on the market because of the rise of virtual companies. [Natalia Merzlyakova - Fotolia.com]
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.